Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate–antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Wilkinson, Joanne; Wade, Alan; Thomas, S. Jane; Jenner, Bartosz; Hodgkinson, Victoria; Coyle, Cathal
• Is Part Of: European journal of gastroenterology & hepatology. Volume 31:Issue 1(2019)
• Publication Date: 2019-01
• Subjects: adult -- alginates -- double-blind method -- dyspepsia -- gastroesophageal reflux -- heartburn -- humans -- tablets; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000001258
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Background: The alginate–antacid Gaviscon Double Action (Gaviscon DA) has a combined acid-neutralizing and reflux-suppressing action. Response to treatment in a symptomatic gastro-oesophageal reflux disease (GERD) population has not yet been tested in a large-scale clinical study. Aim: The aim of this study was to assess the efficacy and safety of Gaviscon DA compared with matched placebo tablets in the reduction of upper gastrointestinal symptoms in patients with GERD. Participants and methods: In this multicentre, randomized, double-blind, placebo-controlled study, adults with GERD symptoms ( N =424) received Gaviscon DA or placebo tablets for 7 days. The primary endpoint was a clinically important reduction of at least 1.5 points in the Reflux Disease Questionnaire (RDQ) GERD dimension (combined heartburn/regurgitation) between baseline and the end of the treatment. Secondary endpoints included the change in RDQ score from baseline for individual RDQ dimensions and Overall Treatment Evaluation. Results: A significantly greater proportion of patients treated with Gaviscon DA met the primary endpoint compared with placebo (47.8 vs. 33.2%, respectively, P =0.0031; odds ratio: 1.85, 95% confidence interval: 1.23–2.78). A significant treatment effect was also observed for heartburn, regurgitation and dyspepsia individually. Patients in the Gaviscon DA group rated their overall treatment response greater than patients in the placebo group [mean Overall Treatment Evaluation (SD): 3.2 (3.08) vs. 2.2 (3.34); P <0.001]. No notable differences in the incidence of adverse events were observed between treatments. Conclusion: The alginate–antacid combination, Gaviscon DA, is an effective and well-tolerated treatment to reduce reflux symptoms and associated dyspepsia in symptomatic GERD patients. Abstract : Supplemental Digital Content is available in the text.